Floatz logo

Nk Cell

Sarcoma

National Cancer Institute (NCI)Cell therapyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

110 Active assets in the Sarcoma cohort.

View all 50

Same molecule, other indications

Nk Cell is also rated in:

acute myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
smoldering plasma cell myelomaDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →